clinical trial · NCT07327697
A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects
Qilu Pharmaceutical Co., Ltd.·phase1·not yet recruiting·n = 178
Healthy ParticipantsQL2302Tezspire
brief summary
This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2302 versus Tezspire®（Tezepelumab） in healthy subjects after a single dose.
started
Dec 22, 2025
primary completion
Jul 1, 2026
completion
Sep 1, 2026
last updated
Jan 8, 2026
official title
A Randomized, Double-blinded, Parallel, Positive-controlled Study to Compare the Pharmacokinetic, Safety and Immunogenicity of Single-dose QL2302 vs. Tezspire ® in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol